Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,849 | 6 | 62.4% |
| Unspecified | $9,563 | 1 | 35.4% |
| Travel and Lodging | $447.66 | 2 | 1.7% |
| Food and Beverage | $147.00 | 1 | 0.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $14,513 | 3 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $6,263 | 2 | $0 (2021) |
| Indivior Inc. | $5,486 | 1 | $0 (2017) |
| Heron Therapeutics, Inc. | $371.38 | 2 | $0 (2018) |
| BioMarin Pharmaceutical Inc. | $223.28 | 1 | $0 (2018) |
| Alkermes, Inc. | $150.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $6,263 | 2 | Boehringer Ingelheim International GmbH ($6,263) |
| 2020 | $4,950 | 2 | AstraZeneca UK Limited ($4,950) |
| 2019 | $9,563 | 1 | AstraZeneca UK Limited ($9,563) |
| 2018 | $594.66 | 3 | Heron Therapeutics, Inc. ($371.38) |
| 2017 | $5,636 | 2 | Indivior Inc. ($5,486) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2021 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 03/15/2021 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,912.50 | General |
| 10/01/2020 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,137.50 | General |
| 06/18/2020 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,812.50 | General |
| 03/14/2019 | AstraZeneca UK Limited | — | — | Cash or cash equivalent | $9,562.50 | Research |
| Study: This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR and Rad3 related protein kinase and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 in second or third line setting in patients with Triple negative breast cancer prospectively stratified by presence absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway | ||||||
| 11/30/2018 | Heron Therapeutics, Inc. | HTX-011 (Drug) | Food and Beverage | In-kind items and services | $147.00 | General |
| 11/29/2018 | Heron Therapeutics, Inc. | HTX-011 (Drug) | Travel and Lodging | In-kind items and services | $224.38 | General |
| 03/14/2018 | BioMarin Pharmaceutical Inc. | BMN 111 (Biological) | Travel and Lodging | In-kind items and services | $223.28 | General |
| Category: Achondroplasia | ||||||
| 11/21/2017 | Indivior Inc. | SUBOXONE SUBLINGUAL FILM (Drug) | Consulting Fee | Cash or cash equivalent | $5,486.40 | General |
| Category: OUD | ||||||
| 08/29/2017 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR and Rad3 related protein kinase and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 in second or third line setting in patients with Triple negative breast cancer prospectively stratified by presence absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway | AstraZeneca UK Limited | $9,563 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 68 | 103 | $13,073 | $4,210 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 33 | 60 | $4,763 | $1,643 | 34.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 28 | $4,086 | $1,383 | 33.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 15 | $4,223 | $1,184 | 28.0% |
About Dr. Scott Emerson, DO
Dr. Scott Emerson, DO is a Psychiatry healthcare provider based in Asheville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1033361043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Emerson, DO has received a total of $27,006 in payments from pharmaceutical and medical device companies, with $6,263 received in 2021. These payments were reported across 10 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($16,849).
As a Medicare-enrolled provider, Emerson has provided services to 68 Medicare beneficiaries, totaling 103 services with total Medicare billing of $4,210. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Location Asheville, NC
- Active Since 10/21/2008
- Last Updated 04/15/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1033361043
Products in Payments
- SUBOXONE SUBLINGUAL FILM (Drug) $5,486
- HTX-011 (Drug) $371.38
- BMN 111 (Biological) $223.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Asheville
Gregory Narron, Md, MD
Psychiatry — Payments: $8,111
Dr. Stephen Buie, M.d, M.D
Psychiatry — Payments: $5,987
Marisa Isbell, Pa, PA
Psychiatry — Payments: $5,556
Dr. Ricardo Bierrenbach Decastro, M.d, M.D
Psychiatry — Payments: $5,123
Michael Murray, Do-Phd, DO-PHD
Psychiatry — Payments: $4,023
Lawrence Jones, M.d, M.D
Psychiatry — Payments: $3,745